TISSUE REPAIR

ANNUAL GENERAL MEETING · NOVEMBER 2026

Company update

Moving from R&D into commercialisation

Tony Charara, Chief Executive Officer and Co founder

SEPTEMBER QUARTER 2026

The quarter at a glance

c113

patients randomised in the US Phase III chronic wound trial (to date)

March 2027

target for the FDA 510(k) device submission

~US$1,270

indicated US reimbursement per 10g tube in chronic wound clinics

3

TR Pro+ formats now in market in Australia: 10g, 30g and 200g

TR Pro+ growth returning

Aesthetics distribution taken back from distributor; Quarterly sales now on track for 180k this quarter

API

Contracted Australian API partner to commence long term production of API in H1 2027

THE SHIFT

Tissue Repair is moving from R&D into full commercialisation

Should the Phase III trial be brought to a close and the company pursue a device pathway, the balance of funds will go to a full commercial launch in Australia, with medical, pharmacy and direct to consumer as the main test market for the brand and technology platform prior to building global distribution through partners, based on the data and learnings from the Australian home market

THEN

Research, clinical trials and building the evidence base

NEXT

Device approvals: FDA 510(k) and CE Mark Class II
product portfolio covering Aesthetics, Acute wounds and Chronic wounds

NOW BUILDING

Full launch in Australia followed by partners for global markets

REGULATORY STRATEGY

Why the device pathway

Faster and lower cost

A device approval does not need the full Phase III recruitment plan that a new drug approval requires.

Stronger economics

US reimbursement changes in April 2026 indicate about US$1,270 per 10g tube in wound clinic settings.

A larger market

Device approval opens the substantially larger global acute wound market.

Regulatory timeline

Q1 2027	Non clinical reports complete: chemical characterisation, biological evaluation, packaging integrity
April 2027	FDA 510(k) submission
Thereafter	CE Mark Class II submission for Europe
6 to 12 months	Estimated time to FDA approval after submission

EVIDENCE BASE

The evidence behind the product

~150

patients in Phase I and Phase II chronic wound trials

NEW

c125 in p3

Estimated patients randomized in the Phase III trial end of quarter

c300

Across P2 and P3 Patients overall in randomised trials supporting the commercial phase for chronic wounds

60%

greater wound area reduction than placebo, 147 patients (p=0.03)

20%-30% closure

higher complete closure than placebo, Phase IIB, targeting same signal in P3

Doubling of skin quality

A randomised, double blind trial in 40 subjects after CO2 laser resurfacing showed better healing and skin quality.

How it works

Glucoprime® activates macrophages: 45% more M2 repair cells and a 37% smaller wound gape at day 7 (UniSA mouse model).

Sources: company clinical data; Wu et al. 2022; Mills et al., UniSA (submitted)

BRAND ARCHITECTURE

Multiple sub-brands for the commercial phase - supporting new markets, new products, new channels

Each sub-brand targets a wound type and channel, with its own products. All powered by Glucoprime®.

TR Pro+

Aesthetic aftercare after cosmetic procedures

CHANNEL

Aesthetic clinics

STATUS

Existing product, in market today

NEW SUB-BRAND · NEW MARKET

New Brand

Acute wounds, mild burns and similar injuries

CHANNEL

Medical, pharmacy and D2C

STATUS

New brand, proposed for the Australian launch

NEW SUB-BRAND · NEW MARKET

New Brand

Chronic wounds

CHANNEL

[Channel TBC]

STATUS

Device or drug product; FDA 510(k) targeted April 2027

TR Sil (next generation silicon) and TR Ferrin (next generation bruising) for medical and pharmacy channels, all powered by Glucoprime®. will likely sit new brand

COMMERCIALISATION · AUSTRALIA

Australia: our commercial test and home market

A full launch across three channels, with pharmacy as a key test of consumer demand.

DIRECT

Aesthetic clinics

- Direct distribution resumed in September 2026
- growth returning under company stewardship in a significant way
- 10g, 30g and 200g professional back bar in market
- Close clinic relationships to build a new category of active repair and recovery, post procedure

NEW DISTRIBUTION

Medical

- Small Distribution continues in the medical channel
- We will launch formally in this channel with new sub-brand and explore e-tailers, DTC and pharmacy
- Medical Advisory Board: 8 KOLs plus Chair, Dr Steven Liew. First board meeting occurred in November 2026. KOLs highly engaged

KEY TEST MARKET

Pharmacy

- TGA listed medicine (AUST L 456187), so it can be stocked in pharmacy
- Prove sell through, repeat purchase and pharmacist recommendation
- Launch timing [TBC]

COMMERCIALISATION · GLOBAL

Global markets through distribution partners

MARKET

United States

- FDA 510(k) submission targeted for April 2027
- Reimbursement framework in place for wound clinics
- approval gives us acute wounds and aesthetic right to market

MARKET

Europe, Middle East and Asia

- CE Mark Class II submission to follow the 510(k)
- One approval opens multiple markets

GLOBAL GROWTH MODEL

Partners, not our own sales forces

- Established distributors carry sales and market access
- Australian results and sales playbook become the evidence pack for partners
- Clinical data supports market entry

WHAT COMES NEXT

Milestones ahead

Timing	Milestone
Early November 2026	First Medical Advisory Board meeting
Q1 2027	Non clinical test reports complete for the device submission
April 2027	FDA 510(k) submission
2027, after the 510(k)	CE Mark Class II submission
6 to 12 months after submission	Estimated FDA approval decision
H2 2027	Phase III trial decision
H2 2027	Scale up Manufacturing for API online in Australia
H1 2028	Australian pharmacy launch
H1 2028 (timing TBC)	New brands in acute wounds and chronic wounds to be launched

This presentation contains forward looking statements. Timelines and outcomes are estimates and subject to regulatory, clinical and commercial risks.

LEADERSHIP

We have the team to move from an R&D shop to commercialisation

BOARD OF DIRECTORS

Alistair McKeough

Independent Non-Executive Chair

Executive and lawyer; 20 years advising founders on growth and and scale in regulated businesses

Tony Charara

Co-founder, CEO and Executive Director

Ex JPMorgan; co-founder of Mable; EY Entrepreneur of the Year technology 2025, top 100 innovators by the Australian 2023

Peter Scutt

Co-founder and Executive Director

Former Novogen director, US venture capital founder and Bankers Trust partner and co founder of mable: top 100 innovators by the Australian 2023

Patryk Kania

Independent Non-Executive Director

20+ years in medtech and pharma; Smith+Nephew, Abbott, J&J and Roche

MANAGEMENT AND ADVISERS

NEW APPOINTMENT

To be announced

Chief Commercial Officer

Cosmetics and pharma background lead growth from zero to $100m ARR

Darrell Reed

Head of Scientific Affairs

Excperienced medical affairs leader with a strong background in clinical research strategy and product commercialisation ex Bayer

Sarika Namjoshi

COO and VP of CMC

Experienced pharmaceutical executive with expertise in chemistry, manufacturing and controls (CMC) product development and regulatory strategy

Advisers

Medical Advisory Board, Chair Dr Steven Liew ·
Sushma Kejriwal, Company Secretary